| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6159415 | The Journal of Urology | 2012 | 8 Pages |
Abstract
Recent findings have continued to lend strong support to the value of extended lymphadenectomy, and 2 ongoing phase III trials will help determine the survival benefit of extended lymphadenectomy. Further improvements in preoperative risk stratification, including advances in imaging technology, may help refine decisions regarding the extent of surgery and the use of neoadjuvant chemotherapy in these individuals.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Todd M. Morgan, Samuel D. Kaffenberger, Michael S. Cookson,